CCO — Calmer Co International Share Price
0.000.00%
Last trade - 00:00- AU$11.88m
- AU$13.00m
- AU$4.26m
- 28
- 58
- 46
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -204.86% | ||
| Return on Equity | n/a | ||
| Operating Margin | -51.9% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.77 | 1.17 | 2.05 | 1.78 | 4.26 | n/a | n/a | 87.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
The Calmer Co. International Limited is a health and wellness company with operations in Australia, Fiji, and the USA. The Company produces natural products to reduce anxiety, promote relaxation, improve sleep, and support sports recovery and performance. The company works with farmers to source high quality kava and hemp that is processed into active extracts for business to business (B2B) sales or into finished products across a house of brands. The Company’s brands include Fiji Kava, Taki Mai, and Danodan Hempworks. Its Taki Mai and Fiji Kava brands are focused on expanding the distribution of kava throughout global markets to provide a natural alternative to alcohol and to small molecule sleep and antianxiety prescription medicines. Its Danodan brand offers a patented range of USDA certified organic tinctures, and soon topicals, sold throughout the USA and online for relaxation, sleep, and recovery.
Directors
- Andrew Kelly NEC
- Anthony Noble CEO
- Zane Yoshida MDR
- Brian Casutto MDR (50)
- Jay Stephenson SEC
- Jack Lowenstein NID (61)
- Nicholas Simms NID
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- May 8th, 2014
- Public Since
- December 20th, 2018
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,485,480,742
- Address
- 96 Victoria Street, West End, BRISBANE, 4101
- Web
- https://www.thecalmerco.com/
- Phone
- +61 864891600
- Auditors
- Hall Chadwick QLD
Upcoming Events for CCO
Half Year 2025 Calmer Co International Ltd Earnings Release
Similar to CCO
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Calmer Co International share price?
As of Today at 22:41 UTC, shares in Calmer Co International are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Calmer Co International share price performed this year?
Shares in Calmer Co International last closed at AU$0.01 and the price had moved by +33.33% over the past 365 days. In terms of relative price strength the Calmer Co International share price has outperformed the ASX All Ordinaries Index by +10.73% over the past year.
What are the analyst and broker recommendations for Calmer Co International?
There is no consensus recommendation for this security.
Find out moreWhat is the Calmer Co International dividend yield?
Calmer Co International does not currently pay a dividend.
Does Calmer Co International pay a dividend?
Calmer Co International does not currently pay a dividend.
When does Calmer Co International next pay dividends?
Calmer Co International does not currently pay a dividend.
How do I buy Calmer Co International shares?
To buy shares in Calmer Co International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Calmer Co International?
As of the previous close price of AU$0.01, shares in Calmer Co International had a market capitalisation of AU$11.88m.
Where are Calmer Co International shares listed?
Here are the trading details for Calmer Co International:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CCO
What kind of share is Calmer Co International?
Based on an overall assessment of its quality, value and momentum Calmer Co International is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Calmer Co International share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Calmer Co International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calmer Co International. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +22.16%.
As of the last closing price of AU$0.01, shares in Calmer Co International were trading +12.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Calmer Co International PE Ratio?
The Calmer Co International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Calmer Co International?
Calmer Co International's management team is headed by:
- Andrew Kelly - NEC
- Anthony Noble - CEO
- Zane Yoshida - MDR
- Brian Casutto - MDR
- Jay Stephenson - SEC
- Jack Lowenstein - NID
- Nicholas Simms - NID